Awakn Life Sciences (TSE:AWKN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Awakn Life Sciences has reported promising preclinical results for its aminoindane compound, AW21003, which could offer new therapeutic options for PTSD. The study highlights the compound’s potential to enhance pro-social behavior without the safety concerns associated with other treatments like MDMA. This progress paves the way for further research and development in collaboration with Graft Polymer and Concept Life Sciences.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue